Key points are not available for this paper at this time.
SUMMARY: Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.
Donaldson et al. (Tue,) studied this question.